


WHAT IS CLAIMED IS:

1. A compound of formula I:



wherein R_1 and R_2 are each independently H, alkyl, cycloalkyl, aryl, heteroaryl, $-C(O)R_7$, $-OR_7$ or $-C(O)NR_7R_8$, wherein the alkyl, cycloalkyl, aryl and heteroaryl groups may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, $-OH$, $-OR_7$, a heteroalicyclic group, and a trihaloalkyl group;

R_3 and R_4 are each independently selected from the group consisting of H, halo, alkyl, aryl, heteroaryl, heteroalicyclic, $-OH$, $-OR_7$, $-NR_7R_8$, $-(CH_2)_nC(O)OR_7$, $-SO_2R_7$, $-(CH_2)_nC(O)NR_7R_8$, $-C(S)NR_7R_8$, $-C(O)R_7$, $-NR_7C(O)R_8$, $-NHC(O)OR_8$, $-NR_7C(O)NR_9R_8$, $-SO_2NR_7R_8$, $-OC(O)OR_7$, $-OC(O)NR_7R_8$, CN and NO_2 , wherein the alkyl, aryl, heteroaryl and heteroalicyclic groups may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_9R_8$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

R_5 is selected from the group consisting of H, aryl, or halo, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_9R_8$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

wherein at least one of R_3 , R_4 and R_5 is an aryl;


R_6 is H;

R_7 , R_8 and R_9 are independently H, alkyl, aralkyl, heterocycloalkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, $-OH$, alkoxy, amino, $-NO_2$ and $-CN$;

alternatively, NR_7R_8 can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than 4 of the heteroatoms (N, O, or S), and the cyclic structure formed about NR_7R_8 may be substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, heteroalicyclic, aryl, heteroaryl and halo; and wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

2. A compound of the formula I:



wherein R_1 and R_2 are each independently H, alkyl, cycloalkyl, aryl, heteroaryl, $-\text{C}(\text{O})\text{R}_7$, $-\text{OR}_7$ or $-\text{C}(\text{O})\text{NR}_7\text{R}_8$ wherein the alkyl, cycloalkyl, aryl and heteroaryl groups may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, $-\text{OH}$, $-\text{OR}_7$, a heteroalicyclic group, and a trihaloalkyl group;

R_3 and R_4 are each H;

R_5 is aryl, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-\text{OR}_7$, $-\text{NR}_7\text{R}_8$, $-\text{NR}_7\text{C}(\text{O})\text{R}_8$, aryl, $-\text{C}(\text{O})\text{OR}_7$, cycloalkyl, haloalkyl, haloalkoxy, $-\text{C}(\text{O})\text{R}_7$, $-\text{NR}_7\text{C}(\text{O})\text{OR}_8$, $-\text{SO}_2\text{R}_7$, $-\text{NR}_7\text{C}(\text{O})\text{NR}_9\text{R}_8$, $-\text{C}(\text{O})\text{NR}_7\text{R}_8$ and $-\text{SO}_2\text{NR}_7\text{R}_8$;

R_6 is H;

R_7 , R_8 and R_9 are independently H, alkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, $-\text{OH}$, alkoxy, amino, $-\text{NO}_2$ and $-\text{CN}$;


alternatively, NR_7R_8 can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than four heteroatoms (N, O, or S), and the cyclic structure formed about NR_7R_8

may be substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, heteroalicyclic, aryl, heteroaryl and halo; and

wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

3. A compound of formula I:



wherein R_1 and R_2 are each independently H, alkyl, cycloalkyl, aryl, heteroaryl, $-C(O)R_7$, $-OR_7$ or $-C(O)NR_7R_8$ wherein the alkyl, cycloalkyl, aryl and heteroaryl groups may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, $-OH$, $-OR_7$, a heteroalicyclic group, and a trihaloalkyl group;

R_3 is aryl, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_9R_8$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

R_4 is H;

R_5 is selected from the group consisting of H, aryl or halo, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_9R_8$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

R_6 is H;

R_7 , R_8 and R_9 are independently H, alkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, $-OH$, alkoxy, amino, $-NO_2$ and $-CN$;


alternatively, NR_7R_8 can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no

more than four heteroatoms (N, O, or S), and the cyclic structure formed about NR_7R_8 may be substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, heteroalicyclic, aryl, heteroaryl and halo; and

wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

4. A compound of formula I:



wherein R_1 and R_2 are each independently H, alkyl, cycloalkyl, aryl, heteroaryl, $-\text{C}(\text{O})\text{R}_7$, $-\text{OR}_7$ or $-\text{C}(\text{O})\text{NR}_7\text{R}_8$ wherein the alkyl, cycloalkyl, aryl and heteroaryl groups may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, $-\text{OH}$, $-\text{OR}_7$, a heteroalicyclic group, and a trihaloalkyl group;

R_3 is H;

R_4 is aryl, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-\text{OR}_7$, $-\text{NR}_7\text{R}_8$, $-\text{NR}_7\text{C}(\text{O})\text{R}_8$, aryl, $-\text{C}(\text{O})\text{OR}_7$, cycloalkyl, haloalkyl, haloalkoxy, $-\text{C}(\text{O})\text{R}_7$, $-\text{NR}_7\text{C}(\text{O})\text{OR}_8$, $-\text{SO}_2\text{R}_7$, $-\text{NR}_7\text{C}(\text{O})\text{NR}_9\text{R}_8$, $-\text{C}(\text{O})\text{NR}_7\text{R}_8$ and $-\text{SO}_2\text{NR}_7\text{R}_8$;

R_5 is selected from the group consisting of H, aryl or halo, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-\text{OR}_7$, $-\text{NR}_7\text{R}_8$, $-\text{NR}_7\text{C}(\text{O})\text{R}_8$, aryl, $-\text{C}(\text{O})\text{OR}_7$, cycloalkyl, haloalkyl, haloalkoxy, $-\text{C}(\text{O})\text{R}_7$, $-\text{NR}_7\text{C}(\text{O})\text{OR}_8$, $-\text{SO}_2\text{R}_7$, $-\text{NR}_7\text{C}(\text{O})\text{NR}_9\text{R}_8$, $-\text{C}(\text{O})\text{NR}_7\text{R}_8$ and $-\text{SO}_2\text{NR}_7\text{R}_8$;

R_6 is H;

R_7 , R_8 and R_9 are independently H, alkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, hydroxy, alkoxy, amino, $-\text{NO}_2$ and $-\text{CN}$;

alternatively, NR₇R₈ can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than four heteroatoms (N, O, or S), and the cyclic structure formed about NR₇R₈ may be substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, hydroxy, heteroalicyclic, heterocycloalkyl, aryl, heteroaryl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl and halo; and

wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1, wherein R₄ and R₅ are optionally substituted aryl.

6. A compound selected from the group consisting of:

Methyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

3-Phenyl-imidazo[1,2-a]pyrazin-8-ylamine,

3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-ylamine,

N-[4-(4-trifluoromethyl-benzamide-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-4-trifluoromethyl-benzamide,

N-[4-(8-Amino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-4-trifluoromethyl-benzamide,

(4-Methoxy-phenyl)-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Dimethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Isopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Isopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Butyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Ethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

(2-Morpholin-4-yl-ethyl)-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Benzyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

2-(3-Phenyl-imidazo[1,2-a]pyrazin-8-ylamino)-ethanol,

1-Butyl-3-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-urea,

N-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide,

N-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide,

2,6-Dimethyl-4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,
 3-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-ylamine,
 Cyclopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,
 [3-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 Methyl-[3-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
 Methyl-[3-(3-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
 Methyl-[3-(2-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
 (3-Biphenyl-2-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,
 [3-(2-Benzyloxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,
 [3-(3-Isopropyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 [3-(4-tert-Butyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 [3-(4-Cyclohexyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 [3-(3,5-Bis-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-
 amine,
 3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,
 3-(8-Methylamino-imidazo[1,2-a]pyrazin-4-yl)-benzoic acid,
 Methyl-(3-o-tolyl-imidazo[1,2-a]pyrazin-8-yl)-amine,
 [4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl
 ester,
 Methyl-[3-(4-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
 [3-(2,4-Difluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 [3-(3,4-Dichloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 [3-(3-Fluoro-4-methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 (3-Biphenyl-4-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,
 (3-Biphenyl-3-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,
 [3-(4-Benzyloxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 Methyl-(3-naphthalen-1-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,
 [3-(2-Chloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 N-[3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]acetamide,

Methyl-[3-(2-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
 Methyl-[3-(3-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
 Cyclopropyl-{3-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine,
 3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,
 Methyl-[3-(4-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
 [3-(2-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 [3-(3,4-Difluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 (3-Benzo[1,3]dioxol-5-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,
 [3-(3-Chloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 [3-(4-Methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 [3-(2-Methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 Methyl-[3-(4-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
 [3-(4-Benzyloxy-3-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 [3-(4-Isopropyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
 [3-(3,5-Bis-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,
 Cyclopropyl-[3-(3,4-dichloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
 3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,
 Methyl-{3-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine,
 Cyclopropyl-{3-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine,
 Cyclopropyl-[3-(4-dimethylamino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
 Cyclopropyl-[3-(4-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,
 [4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,
 N-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide,
 [3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,

[3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
Methyl-(3-naphthalen-2-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,
4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,
[3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,
Methyl-{3-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine,
[3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,
4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-N-(2-morpholin-4-yl-ethyl)-benzamide,
4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-N-(3-morpholin-4-yl-propyl)-benzamide,
4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-N-(3-pyrrolidin-1-yl-propyl)-benzamide,
1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,
(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
(S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
(S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,
(S)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,

4-Pyrrolidin-1-yl-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,
4-Hydroxy-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide
(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
4-Hydroxy-piperidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,
1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,
1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,
1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,
(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
(R)-2-Dimethylaminomethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,
(R)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,
1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

[5-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

Methyl-(5-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Methyl-(5-thiophen-3-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Methylamino-imidazo[1,2-a]pyrazin-5-yl)-phenol,

N-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-5-yl)-phenyl]-acetamide,

[3,5-Bis-(4-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

(3,5-Diphenyl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,

Methyl-(6-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Methylamino-imidazo[1,2-a]pyrazin-6-yl)-phenol,

6-Phenyl-imidazo[1,2-a]pyrazin-8-ylamine and

Dimethyl-(3-phenyl-imidazo[1,2-a]pyrazin-5-yl)-amine,

or a prodrug or pharmaceutically acceptable salt thereof.

7. A compound selected from the group consisting of:

Methyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Ethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Cyclopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,

[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,

[3-(3-Fluoro-4-methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Methyl-[3-(4-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

[3-(4-Benzoyloxy-3-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

Cyclopropyl-[3-(4-dimethylamino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,

[4-(8-Cyclopropylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,

[3-(3-Amino-phenyl)-imidazo[1,2-*a*]pyrazin-8-yl]-cyclopropyl-amine,

[3-(4-Amino-phenyl)-imidazo[1,2-*a*]pyrazin-8-yl]-methyl-amine,

Methyl-(3-naphthalen-2-yl-imidazo[1,2-*a*]pyrazin-8-yl)-amine,

[3-(4-Amino-phenyl)-imidazo[1,2-*a*]pyrazin-8-yl]-cyclopropyl-amine,

[3-(3-Amino-phenyl)-imidazo[1,2-*a*]pyrazin-8-yl]-methyl-amine,

3-(8-Methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenol,

1-[3-(8-Methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-amide,

(S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-amide,

(S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

(S)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-amide,

(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,

4-Pyrrolidin-1-yl-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

4-Hydroxy-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-amide,

1-[3-(8-Methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

1-[3-(8-Methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,

1-[3-(8-Methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,

1-[3-(8-Methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

1-[4-(8-Methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,

(*R*)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Cyclopropylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea and

1-[4-(8-Cyclopropylamino-imidazo[1,2-*a*]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

or a prodrug or pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt of a compound of claim 1 and pharmaceutically acceptable carrier or excipient.

9. A method for the modulation of the catalytic activity of a protein kinase comprising contacting the protein kinase with a compound or a pharmaceutically acceptable salt of a compound claim 1.

10. The method of claim 9, wherein the protein kinase is selected from the group consisting of a receptor tyrosine kinase, a non-receptor tyrosine kinase and a serine-threonine kinase.

11. A method for treating or preventing a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt of a compound of claim 1 and a pharmaceutically acceptable carrier or excipient to the organism.

12. The method of claim 11, wherein the protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder and a serine-threonine kinase related disorder.

13. The method of claim 11, the protein kinase related disorder is selected from the group consisting of an PDGFR related disorder and a flk related disorder.

14. The method of claim 11, wherein the protein kinase related disorder is a cancer selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.

15. The method of claim 11, wherein the protein kinase related disorder is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis (including pulmonary fibrosis), psoriasis, von Heppel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.

16. The method of claim 11, wherein the organism treated is a human.